India's electric two-wheeler (e2W) manufacturers have urged the government to extend subsidies under the PM E-Drive (Electric Drive Revolution in Innovative Vehicle Enhancement) scheme beyond March 2026, cautioning that a withdrawal could slow near-term demand even as confidence in long-term electric mobility adoption remains intact.
India's electric passenger vehicle (ePV) market has expanded sharply over the past five years, with registrations rising from just 3,252 units in 2020 to about 170,000 in 2025. Throughout this scale-up, southern states have remained the bedrock of adoption, consistently contributing around one-third of national electric vehicle (EV) registrations - emphasising the region's role as the structural backbone of India's EV transition.
India's two-wheeler industry is seen growing 6-9% in 2026, though a proposed ABS mandate for sub-125cc models could push up prices and temper volumes.
Data from used-car platforms suggest that buyer preferences have remained broadly stable post-GST, with SUVs retaining their dominance even as price adjustments played out across segments.
Network scale seen as central to tapping smaller markets.
The US Food and Drug Administration (USFDA) recorded a significant decline in serious regulatory findings at Indian drug manufacturing facilities between January and December 2025. Data reveals that 'official action indicated' (OAI) cases - the most severe classification - nearly halved over the past year.
India's diagnostics sector is accelerating capacity addition and geographic expansion, as large chains and regional players invest in new laboratories, integrated centres and dense sample collection networks to tap rising demand for preventive, advanced and precision testing.
'In India's competitive automotive market, staying relevant means continuously raising the bar.'
'India is clearly moving toward more targeted treatment pathways in high-burden cancers.'
Emcure Pharmaceuticals on Monday said it saw Poviztra, its newly launched semaglutide brand, as a "long-term" opportunity in India's fast-evolving obesity and cardiometabolic therapy market, even as price competition in the glucagon-like peptide-1 (GLP-1) segment intensified.
Indian automakers are reviving legacy nameplates to leverage brand recall and stand out in a crowded market, as classic badges like Sierra, Safari, Baleno and Scorpio return to attract buyers.
Starting January, the market is expected to welcome models like the Tata Punch 2025 which is expected to be around 6 lakh, Mahindra BE 07 EV around 29 lakh, Maruti WagonR Electric around 8.5 lakh, Toyota 3-Row SUV around 14 lakh, and Volkswagen Tera to be around 8 lakh.
Mahindra & Mahindra (M&M) is stepping beyond vehicle manufacturing to build a national electric-mobility ecosystem.
Tata Motors Passenger Vehicles (TMPV) on Friday reported a 13 per cent year-on-year (Y-o-Y) decline in consolidated revenue from operations for the second quarter of 2025-26 (Q2FY26), largely due to the cyberattack on its subsidiary Jaguar Land Rover (JLR) in late August that forced a shutdown of its manufacturing operations for over five weeks.
Yamaha expects its first EVs to hit showrooms by the last quarter of FY26 (January - March), once network readiness is complete.
Tata Motors' commercial vehicle (CV) business debuted on the BSE on Wednesday, completing the automaker's long-planned demerger into separate listed entities for its passenger and CV operations.
Grant Thornton Bharat's latest survey indicates that hybrids are set to consolidate market share this festive season, bridging the gap between conventional petrol engines and the emerging electric vehicle segment.
Between January and August 2025, over 65,000 units of the Bolero were sold, making it the third-highest contributor to Mahindra's overall SUV sales. Bolero annually achieves sales of over 1 lakh units.
'Faulty alarms, delays in shutting off oxygen, poor electrical maintenance and staff untrained for emergencies. These are not isolated incidents but reflect a larger pattern of weak oversight.'
If cashless services are suspended, AHPI said, its member hospitals will continue to treat Star Health policyholders, but patients will have to pay upfront and later seek reimbursements directly from the insurer.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances